摘要
目的观察多西他赛联合洛铂化疗方案治疗宫颈癌的疗效和毒副反应。方法从该院宫颈癌患者中选取宫颈癌Ⅰb2~Ⅱb期68例患者,回顾分析新辅助化疗的疗效及副作用。结果实验组（洛铂联合多西他赛）32例中,完全缓解（CR）4例,部分缓解（PR）24例,稳定（SD）4例,进展（PD）0例,总有效率87.5%,主要不良反应为骨髓抑制、恶心、呕吐,但均可耐受。结论多西他赛联合洛铂化疗方案治疗宫颈癌有较好疗效,不良反应可耐受,肾毒性少。
[ Objective ] To evaluate the effect of combination chemotherapy of Lobaplatin （LBP） combined with Docetaxel chemotherapy in the treatment of cervical cancer and adverse reaction. [Methods ] Select 68 patients in the period Ⅰb2 to Ⅱ b from the cervical cancer patients in our hospital, review and analyze the effect of neoadjuvant chemotherapy and adverse reaction. [Results] Among the 32 patients in the test group （Lobaplatin （LBP） plus Docetaxel）, 4 patients are complete remission （CR）, 24 patients are partial remission （PR）, 4 patients are steady （SD）, none have progressive disease （PD）, the total effective rate 87.5%, major ad- verse reactions are myelosuppression, nausea, vomiting, but all can tolerate. [Conclusion] Lobaplatin （LBP） plus Docetaxel is effective for cervical cancer, the adverse reaction is tolerated and the renal toxicity is dight.
出处
《中国现代医学杂志》
CAS
CSCD
北大核心
2014年第23期84-87,共4页
China Journal of Modern Medicine
